Xichun Hu
A breast medical oncologist who has led Chinese trials of chemotherapy, CDK4/6 inhibitors, and ADCs in advanced breast cancer.
Xichun Hu directs breast medical oncology at FUSCC and has been principal investigator on trials of platinum-based chemotherapy in TNBC, dalpiciclib, and new antibody-drug conjugates including sacituzumab tirumotecan and trastuzumab rezetecan.
| Title | Journal | Year |
|---|---|---|
| Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006) | Lancet Oncology | 2015 |
Pages like this
not linked directly; found by shared links- PersonYi-Zhou Jiang
Shares Fudan University Shanghai Cancer Center, Triple-negative breast cancer (TNBC).
- CompanySichuan Kelun-Biotech
Shares Sacituzumab tirumotecan, Triple-negative breast cancer (TNBC).
- PersonShaoli Song
Shares Fudan University Shanghai Cancer Center, Triple-negative breast cancer (TNBC).
- PersonKan Yonemori
Shares DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer, HR-positive / HER2-negative breast cancer.
- PersonZhi-Ming Shao
Shares Fudan University Shanghai Cancer Center, Triple-negative breast cancer (TNBC).
- TechnologyTROP2 PET
Shares Fudan University Shanghai Cancer Center, Sacituzumab tirumotecan, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
- PairingPlatinum chemotherapy in HRD tumours
Shares Platinum agents, Triple-negative breast cancer (TNBC).
- PersonGiuseppe Curigliano
Shares DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.